ProCE Banner Activity


How to Treat CSPC: Current Data, Case Discussion, and Future Perspectives


Watch this interactive webcast to learn from a urology expert how to optimally care for patients with hormone-sensitive prostate cancer through a series of case discussions across the spectrum of disease.

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: September 20, 2023

Expiration: September 19, 2024



Daniel Saltzstein

Daniel Saltzstein, MD

Medical Director of Research
Director of the Advanced Therapeutic Clinic
Urology San Antonio
Clinical Assistant Professor
The University of Texas Health Science Center at San Antonio
San Antonio, Texas 

Provided by

Provided by Clinical Care Options, LLC 

ProCE Banner


Supported by an educational grant from Myovant Sciences and Pfizer Inc. 

Myovant Sciences

Pfizer, Inc.

Target Audience

This program is intended for urologists and other healthcare professionals who care for patients with prostate cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate new agents and recent findings into the treatment of patients with castration-sensitive prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare the mechanism of action and toxicity profiles associated with luteinizing hormone-releasing hormone (LHRH) agonists, gonadotropin-releasing hormone (GnRH) receptor antagonists, and the AR-targeted agents abiraterone acetate, apalutamide, and enzalutamide for castration-sensitive prostate cancer

  • Plan optimal, individualized sequential therapeutic strategies for nonmetastatic or metastatic castration-sensitive prostate cancer, considering all available agents, clinical data, and expert recommendations

  • Apply cardioprotective strategies to reduce risk in patients with prostate cancer receiving ADT
  • Evaluate the clinical potential of investigational therapeutic approaches for patients with castration-sensitive prostate cancer


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Daniel Saltzstein, MD

Medical Director of Research
Director of the Advanced Therapeutic Clinic
Urology San Antonio
Clinical Assistant Professor
The University of Texas Health Science Center at San Antonio
San Antonio, Texas 

Daniel Saltzstein, MD: consultant/advisor/speaker: Dendreon, Janssen, Lantheus, Myovant. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from September 20, 2023, through September 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

Joint Accreditation



In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.